Compare Eli Lilly and Novo Nordisk side by side: valuation, margins, growth, cash and dividends, with the quarterly history of both. Yahoo Finance data, free and no sign-up.
Each column shows figures in that company's reporting currency (shown in the header); they are not converted. Ratios and percentages are currency-independent.
Price, rebased to 100
Eli Lilly499Novo Nordisk76
P/E (TTM)
Eli Lilly38.8×Novo Nordisk9.6×
Both curves start at 100 on the same day, so this compares returns rather than prices. Each week's P/E is the price divided by the earnings per share already reported by that date; loss-making weeks are not drawn.
What analysts expect
Consensus revenue and earnings per share for the periods not yet reported.
Revenue forecast · Eli Lilly
ReportedEstimate
Consensus of 15 analysts for Q3 26 · +26.87% year on year
Revenue forecast · Novo Nordisk
ReportedEstimate
Consensus of 10 analysts for Q3 26 · -2.78% year on year
EPS forecast · Eli Lilly
ReportedEstimate
Consensus of 17 analysts for Q3 26 · +41.48% year on year · adjusted earnings
EPS forecast · Novo Nordisk
ReportedEstimate
Consensus of 4 analysts for Q3 26 · +11.21% year on year · adjusted earnings
Analyst consensus from Yahoo Finance. The dashed bar is the average and the whisker runs from the lowest analyst to the highest. On periods already reported, the green or red line marks what had been expected: below the bar means the company beat it. EPS is measured on an adjusted basis, which is what analysts forecast against and is not the accounting profit in the statements.
Compared over time
Revenue
Eli LillyNovo Nordisk
Net income
Eli LillyNovo Nordisk
Free cash flow
Eli LillyNovo Nordisk
EPS
Eli LillyNovo Nordisk
EBITDA
Eli LillyNovo Nordisk
Novo Nordisk's figures were converted from DKK to USD at the current rate (0.1524) so both fit one axis.
Source: Yahoo Finance. Quarterly history grows automatically over time as new quarters are published.
